Lacosamide as treatment of epileptic seizures - cost utility results for Sweden
Authors:
- 1 March 2010
- journal article
- Published by Hindawi Limited in Acta Neurologica Scandinavica
- Vol. 121 (6) , 406-412
Abstract
To calculate cost per additional quality-adjusted life-year (QALY) for lacosamide as adjunctive treatment for patients with uncontrolled partial-onset seizures as compared to no adjunctive treatment. A decision-tree simulation model was constructed to calculate the number of seizures and health-care utilization for treated and untreated with lacosamide, respectively. Prices from 2007 were used for all costs. All results were calculated for a 24-, 18-, 12- and 6-months follow-up. The cost per additional QALY was estimated to euro 27,641 (24 months). Using a willingness-to-pay threshold for a QALY of euro 50,000 the net marginal value of using lacosamide was estimated to about euro 850,000 per 1000 patients. The estimated cost per QALY gained falls within the range of reported estimates of the willingness-to-pay for an additional QALY. The results imply that lacosamide is cost-effective in the treatment of uncontrolled partial-onset seizures (1 euro approximately 9.6 SEK).Keywords
This publication has 8 references indexed in Scilit:
- Adjunctive lacosamide for partial‐onset seizures: Efficacy and safety results from a randomized controlled trialEpilepsia, 2009
- Economic analysis of newer antiepileptic drugs.CNS Drugs, 2008
- Efficacy and Safety of Oral Lacosamide as Adjunctive Therapy in Adults with Partial‐Onset SeizuresEpilepsia, 2007
- WTP- and QALY-Based Approaches to Valuing Health for Policy: Common Ground and Disputed TerritoryEnvironmental and Resource Economics, 2006
- Willingness to Pay for a Quality-Adjusted Life Year: Implications for Societal Health Care Resource AllocationMedical Decision Making, 2005
- Health related quality of life in adult patients with epilepsy compared with a general reference population in TaiwanEpilepsy Research, 2005
- Cost‐effectiveness acceptability curves – facts, fallacies and frequently asked questionsHealth Economics, 2004
- Adjunctive lamotrigine therapy in patients with refractory seizures: a lifetime cost-utility analysisEuropean Journal of Clinical Pharmacology, 1998